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INTRODUCTION 
Hyponatremia is defined as plasma sodium concentration < 135 meq/1. It 
is a very common disorder occurring in about 22% of hospitalized patients. 
It can be classified on the basis of serum osmolality into hypertonic, 
isotonic and hypotonic type. Hypotonic hyponatremia is further classified into 
hypervolemic, euvolemic and hypovolemic. 
Mild hyponatraemia is generally asymptomatic, but where the decrease in 
serum sodium is marked (<125 mmol/1) or acute (occurring over <48 h), serious 
neurological complications can occur as a result of cerebral oedema. Early 
symptoms of headache, muscular weakness, nausea, lethargy, ataxia and 
confusion can progress to seizures, irreversible neurological damage, coma and 
death, if unrecognized and untreated. In chronic hyponatraemia, cerebral wasting 
of intracellular potassium followed by organic osmolytes reduces cerebral 
swelling, delaying the onset of symptoms. The correction of hyponatraemia 
should be carefully managed, because of its association with the osmotic 
demyelination syndrome (central pontinemyelinolysis). Patients with chronic 
hyponatraemia appear to be particularly vulnerable to this complication. 
Severe hyponatraemia has a high mortality. In order to give correct 
treatment, an accurate clinical assessment must be made, focusing on fluid status, 
chronicity and potential aetiology, along with appropriate investigations. 
  Hyponatremia is common among hospitalized patients and can lead to serious 
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complications, but its assessment is challenging and strategies for its 
management have traditionally been suboptimal. New therapies are emerging 
that promise a more targeted approach to regulating body water and sodium 
balance in patients with this disorder. 
Hyponatremia is especially common in older people. The incidence is 
muchmore in elderly mainly owing to impaired ability to maintain water and 
electrolyte homeostasis in response to diet, drugs and environmental changes. 
Several changes in the mechanisms that regulate water and sodium balance occur 
as a normal part of the aging process, such as decreased glomerular filtration rate, 
decreased renal bloodflow, impaired ability to dilute urine, and impaired water 
excretion. These physiologic changes result in an increased likelihood of 
developing hyponatremia with increasing age. Recent evidence highlights that 
even mild, chronic hyponatremia can lead to cognitive impairment, falls and 
fractures, the latter being in part due to bone demineralization and reduced bone 
quality. Hyponatremia is therefore of special significance in frail older people. 
Management of hyponatremia in elderly individuals is particularly challenging. 
The underlying cause is often multi-factorial, a clearhistory may be difficult to 
obtain and clinical examination is unreliable. Established treatment modalities 
are often ineffective and carry considerable risks, especially ifthe diagnosis of 
underlying causes is incorrect. 
 
3 
 
 
OBJECTIVES 
1. To study clinical features of euvolemic hyponatremia in elderly hospitalized subjects. 
2. To study etiology of euvolemic hyponatremia in elderly hospitalized subjects. 
3. To assess the morbidity and mortality due to hyponatremia. 
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BACKGROUND 
Hyponatremia 
Hyponatraemia is an electrolyte abnormality commonly encountered in 
clinical practice with a daily incidence and prevalence rates of 0.98% and 2.43% 
respectively. Hyponatremia means an excess of body water when comparing with 
body’s sodium content and is frequently defined as a serum sodium concentration 
of less than 135 mEq/L. The incidence of hyponatremia varies depending upon 
the  underlying conditions and the criteria used to define it. When defined as a 
serum sodium concentration of less than 135 mEq/1 hyponatremia is being 
described in 15% to 22% of hospitalized patients. In studies defining it as a 
concentration of 130mEq/L or less, the incidence of hyponatremia is 1% to 4%. 
It is also associated with 60-fold increase in morbidity and mortality 
compared with patients without any evidence of hyponatraemia. Most cases of 
hyponatraemia arises out of water imbalance rather than sodium imbalance. The 
aetiology of most cases of hyponatraemia can be diagnosed from the history, 
physical examination and simple laboratory tests. As aggressive or inappropriate 
management of hyponatraemia proved to be more harmful than the condition 
itself, clinicians should be familiar with the diagnosis and management of various 
forms of hyponatraemia. 
Basic principles of sodium balance 
Plasma sodium concentrations normally average 140 mEq/1 or 
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140mmol/l.Sodium is the principal osmole, determinant in maintaining 
extracellular fluid (ECF) volume and in the regulation of blood pressure and 
osmotic equilibrium. Sodium is also the principal regulatory osmole of the 
effective circulating volume (ECV), that is, the arterial blood volume perfusing 
the tissues. 
The ECF sodium is maintained by the action of Na
+
/K
+
-ATPase.Water can 
freely cross cell membranes to maintain isotonicity between the intracellular fluid 
(ICF) and ECF, but sodium cannot freely cross and requires energy dependent 
pumps to be transported across the cell membranes. 
The plasma sodium concentration is dependent on multiple factors 
including sodium intake, osmolality and tonicity of plasma, the renin angiotensin 
system 
(RAA), total body potassium and water. The following equation depicts 
therelationship between plasma Na
+
 concentration and the total body content of 
sodium,potassium and water (TBW). 
Plasma Na
+
 =
                        
               
 
The primary determinant of plasma osmalility is the concentration of sodium 
salts with minor contributions from glucose and blood urea nitrogen (BUN). 
Plasma osmolality = (2 x [Na
+
]) + ([glucose]/18) + ({BUN}/2.8) 
The [Na
+
] is multiplied by two to account for the accompanying anions 
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(mostly chloride and bicarbonate) that provide electrical neutrality.  
The corrections are made in the glucose concentration and BUN to convert mg/dl 
into mmol/1. As urea is lipid-soluble and equilibrates across the cell membranes, 
it is an ineffective osmole and does not contribute to fluid distribution, and 
therefore it is omitted from calculation of effective plasma osmolality as 
follows:
14 
Effective plasma osmolality = (2x [Na
+
]) + ([glucose]/! 8).Normal plasma 
osmolality varies between 280 and 290mOsm/l. A discrepancy between the 
measured and calculated osmolality is referred to as an osmolal gap.A high 
concentration of osmotically active molecules in plasma such as ethanol, 
mannitol, methanol, ethylene glycol or isopropyl alcohol.leads to significant 
osmolal gap. 
Average sodium intake is 4-5 g/day (173-217 mmol/day). Sodium chloride 
is table salt, which dissolves in water to give sodium and chloride ions. Sodium is 
0.39 weight of sodium chloride. So 1 g of table salt or salt tablets contains 
approximately 400 mg of sodium. One teaspoon of table salt contains about 6 g of 
NaCl with approximately 2.4 g (104mmol) sodium. One gram of sodium yields 
43 mEq of sodium ions, whereas 1 g of sodium chloride yields 17 mEq of sodium 
ions. 
The total amount of filtered sodium load (25,200 mmol or 583 g/day) is the 
product of the glomerular filtration rate (GFR) (1801/day) and plasma sodium 
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concentrations (140 mmol/1). Therefore, to maintain sodium balance with a 
dietary intake of approximately 200 mmol or 3.2 g/day, a total of 25,000 mmol 
(i.e. 99.6% of the filtered load) must be reabsorbed.
 
 
         Proximal tubule reabsorbs about 60-70% of the filtered sodium . 
Ascending limb of the loop of Henle reabsorbs an additional 20-30%. The 
majority of the remaining sodium (5-10%) is reabsorbed in the distal tubule and 
collecting duct, under the  regulation of aldosterone. 
         Sudden decrease in blood volume is sensed by mechanoreceptors in the 
left ventricle, carotid sinus, aortic arch and renal afferent arterioles leading to 
activation of the RAA system, stimulation of thirst and non osmotic release of 
arginine vasopressin. Juxtaglomerular cells of the kidney synthesize and secretes 
renin. Renin isoenzymes have been found in many tissues, including brain, 
adrenals, vascular beds, uterus and placenta,eventhough renin is mainly produced 
by the kidneys 
Renin cleaves its substrate angiotensinogen to generate the angiotensin I, which 
is converted to angiotensin II by angiotensin I-converting enzyme. Angiotensin II 
stimulates aldosterone secretion through the adrenal cortex and also partially 
suppresses renin secretion by a direct effect on the juxtaglomerular cells.
 
Aldosterone increases sodium reabsorption and potassium excretion in the distal 
tubule and the collecting duct of the nephron; the site where ADH controls the 
rate of water reabsorption also. 
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          Tonicity refers to the effect of a solution on the cell volume. An 
isotonic solution doesn’t have any effect on cell volume, whereas hypotonic and 
hypertonic solutions increase and decrease cell volume respectively. Infusion of 
isotonic saline causes volume expansion without changing the plasma osmolality. 
And the steady state is restored by renal sodium excretion,ADH release and thirst 
are not altered. On the other hand, intake of large quantities of NaCl without 
water (e.g. consumption of salted pretzels, potato chips or peanuts) results in an 
elevation in the plasma osmolality and stimulation of thirst and ADH secretion 
leading to ECV expansion. ECF volume expansion will suppress the RAA 
system, resulting in increased urinary sodium excretion.Thus, the maintenance of 
the ECV is dependent on the regulation of sodium balance, while plasma 
osmolality is largely maintained by the regulation of water balance. 
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Aging increases likelihood of hyponatremia 
 
Several  physiologicalchanges occur in the regulation of water and 
sodium balance as a part of the normal aging process, such as decreased 
glomerular filtration rate, decreased renal blood flow, impaired ability to dilute 
urine, and impaired water excretion. These changes result in an increased 
likelihood of developing hyponatremia with increasing age. 
 
older persons are susceptible to stresses on water balance because of the 
age related decrease in total body water (relative and absolute). Average healthy 
30- to 40-year-old persons have a total-body water content of 55 to 60 percent. By 
age 75 to 80 years, the total-body water content has declined to 50 percent, with 
even more of a decline in elderly women.Factors resulting in the increased 
susceptibility to various hemodynamic changes are decreased baroreceptor 
reflexes, less arterial distensibility,, sluggish homeostatic mechanisms. After 
ingestion of water the body fluid compartments are diluted. With less than 1% 
decrease in osmolality, the hypothalamus- pituitary axis responds by inhibiting 
ADH release. In the absence of ADH, the kidney excretes dilute urine. However 
in the presence of inappropriately elevated ADH a relative water excess can 
result in hyponatremia. 
            The thirst mechanism decreases as, age advances which significantly 
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impairs the capacity to maintain homeostasis  thereby intensifying the risk for 
dehydration. The dimunition in thirst is being attributed in part to a defect in an 
opiod mediated thirst center in CNS..Maximal urinary concentrating capacity 
also diminishes with age which also intensifies the risk for dehydration. 
Eventhough ADH release donot have an association with ageing ,there occurs a 
failure of the normal response of kidney to ADH,as indicated by the increased 
level of ADH for any given plasma osmolality.  
The neurohumoral mechanism of fluid and electrolyte balance depends 
upon an intricate interaction between aldosterone, ADH and ANP. Alterations in 
these hormonal levels are partly responsible for the changes in fluid balance with 
aging.  Younger individuals exhibit a diurnal variation for the ADH release with 
increased secretion occurring at night. 
In elderly these diurnal variations are absent. On comparing with younger 
individuals the levels of ADH are increased for any given plasma osmolality.The 
proposed mechanism for these exaggerated ADH response is osmoreceptor 
hypersensitivity. In the aged there is a five fold increase in ANP concentration 
over the basal levels. Increased ANP leads to direct suppression of renin with a 
secondary decrease in angiotensin II and in aldosterone, resulting in renal loss of 
sodium associated with ageing. 
            In elderly the capacity for excreting a water load is delayed.. This 
propensity may contribute to the frequently observed episodes of hyponatremia 
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in hospitalized elderly patients who are receiving hypotonic intravenous fluids or 
whose fluid intake is not properly monitored. 
Other changes in renal physiology and anatomy that increase the elderly 
patient's susceptibility to alterations of water imbalance include decreased renal 
mass, cortical blood flow and glomerular filtration rate, as well as impaired 
responsiveness to sodium balance. 
Accurate appreciation of the etiology of hyponatremia is essential, not only 
for appropriate clinical management but also to prevent development of 
hyponatremia. At present, there are few quality studies reporting etiology of 
hyponatremia in older people. Most reports are from retrospective studies that 
rely on diagnosis made by non-expert clinicians retrospectively reviewing case 
notes, which frequently lack sufficient detail to allow accurate diagnosis. The 
reported commonest cause of hyponatremia is SIADH. However, with the 
increased prevalence of hyponatremia in older people there is no corresponding 
increased prevalence of SIADH. This raises concern that SIADH may be over 
diagnosed, particularly in hypovolemic older people. The etiology of 
hyponatremia in older people is predominantly multifactorial, with patients 
presenting with doubtful signs of hydration. 
         Common underlying causes of hyponatremia include drugs (thiazide 
and loop diuretics, antidepressants, anticonvulsants, non-steroidal 
anti-inflammatories, proton pump inhibitors), co-morbidities (congestive cardiac 
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failure, renal failure, cirrhosis, respiratory infections), fluid overload and volume 
depletion. 
 The impact of a lifetime of accumulated disease and comorbidities must 
also be duly considered in every clinical situation with an elderly patient, in 
addition to age-related physiologic changes. The elderly patient has a diminished 
reserve of water balance and an impaired regulatory mechanism. Thirst sensation, 
concentrating abilities and hormonal modulators of salt and water balance are 
sluggish and highly susceptible to being overtaken by morbid or iatrogenic 
events. 
Classification of hyponatraemic disorders 
Hyponatraemia  is  defined  as  a plasma sodium concentration less 
than135 mEq/1.
13
 Chan ges in plasma sodium are typically inversely proportional 
to the total body water. In most cases, hyponatraemia is the result of retention of 
more water in relation to sodium and potassium with a possible concurrent 
abnormality in sodium balance. The appropriate physiological response to 
hyponatraemia is suppressed ADH release that in turn facilitates the excretion of 
the excess water to restore the normal sodium and water homeostasis. In the 
absence of advanced renal disease limiting water excretion or a massive increase 
in water intake that exceeds water excretory capacity, hyponatraemia is almost 
always because of an inability to suppress ADH. 
To identify the aetiology of hyponatraemia, a systematic algorithm that is 
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based on the measurements of plasma osmolality and an estimation of the volume 
of the total body water should be followed. It is noteworthy that in any given 
patient, multiple aetiologies may contribute to the pathogenesis of 
hyponatraemia. For example, the patient with congestive heart failure (CHF) who 
has ADH secreting lung cancer and develops severe hyperglycaemia would have 
at least three independent causes of hyponatraemia. To facilitate the differential 
diagnosis, the first step in the evaluation of hyponatraemia irrespective of the 
volume status should start by measuring the plasma osmolality. On the basis of 
the osmolality, hyponatraemia is classified as isotonic, hypertonic and hypotonic. 
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Figure 1: Algorithm for classifying hyponatremia 
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Isotonic hyponatraemia 
Isotonic hyponatraemia can be produced by the addition of an isosmotic, 
non-sodium substance to the ECF. It can happen with the use of non-conductive 
flushing solutions that contain glycine or sorbital during transurethral resection of 
the prostate (TURP), bladder irrigation and during laparoscopic surgery and 
hysteroscopy in women. ' Variable quantities of these solutions can be absorbed 
via the prostatic veins. The plasma osmolality changes over time and can be 
either near normal or low. Glycine initially acts as an ineffective osmole (similar 
to urea), raising the plasma osmolality without affecting water distribution 
between the fluid compartments. Osmolal gap is also increased because of the 
excess organic solute. However, when glycine enters the ICF compartment, the 
free water left behind in the ECF can result in symptomatic 
dilutionalhyponatraemia, that is referred to sometimes as the TURP syndrome.  
In patients with normal renal function, metabolism and excretion of the 
excess solute will rapidly correct the hyponatraemia. Hypertonic saline can be 
given if the plasma osmolality is reduced, but may not be effective in patients 
with normal plasma osmolality. In symptomatic patients with relatively normal 
plasma osmolality and in patients with end-stage renal disease, haemodialysis 
will correct the hyponatraemia and remove glycine and its toxic metabolites. 
Pseudohyponatraemia is seen when the sodium concentrations are 
measured by Flame photometry that determines sodium content per litre of 
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plasma. In normal subjects, each litre of plasma contains about 930 ml of water 
(93%) with fats and proteins accounting for the remaining 70 ml (7%). Thus, a 
normal plasma sodium concentration of 140mEq/l represents a concentration in 
the plasma water of 150 mEq/1 as calculated in the following equation. 
 
140 mEq/1 plasma + 0.93 litre of water plasma 
Per litre of plasma = 150 mEq/1 plasma water 
In patients with marked hyperproteinemia greater than lOg/dl, the 
plasmawater fraction may fall as low as 720 ml/1 (< 80%). Plasma osmolality 
remainsisotonic, because lipids and proteins do not substantially affect 
osmolalitymeasurement. In these patients when sodium is measured per litre of 
plasma, thereported sodium concentration will be artificially reduced as the 
specimen containsless plasma water. 
Table 1:  The comparative profile of the laboratory features of various 
conditions of altered plasma tonicity 
Condition Measured plasma 
Na 
Measured 
plasma osmolality 
Effective 
plasma 
osmolality 
True hypotonicity Decreased Decreased Decreased 
Increased non-sodium 1 XF solutes   
Hyperglycaemia Decreased Increased Increased 
Mannitol administration Decreased Increased Increased 
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Glycine, Sorbital Decreased Variable Normal 
Laboratory artifact 
Hyperlipidaemia Decreased Normal Normal 
Hyperproteinemia Decreased Normal Normal 
Gamma-globulins Decreased Normal Normal 
 
      This laboratory artefact of pseudohyponatraemia can be eliminated by the 
direct measurement of serum sodium using ion-selective electrodes (ISE). 
Hyperlipidaemia interferes with ISE as well as now rarely used flame 
photometry measurements. Some interference is seen when triglycerides are >10 
mmol/1, and when triglycerides are > 20 mmol/1 a significant interference in the 
measurement occurs. Laboratories use reagents such as Lipoclear to address this 
issue, but the results need adjusting for volume changes and errors can occur in 
these adjustments. 
Hypertonic hyponatraemia 
Hypertonic hyponatraemia occurs with hyperglycaemia and mannitol 
administration. Glucose and mannitolosmotically pull intracellular water into the 
extracellular space, which dilutes all the ECF electrolytes resulting in 
hyponatraemia. When evaluating hyponatraemia in the presence of 
hyperglycaemia, the corrected sodium concentration should be calculated. The 
sodium concentration falls 1.6mEq/l for every lOOmg/dl (5.5 mmol/1) rise in 
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glucose when the glucose concentration is between 100 (5.5 mmol/1) and 
400mg/dl (22 mmol/1). If the initial glucose concentration is above 400 mg/dl (> 
22 mmol/1), the sodium concentration falls 2.4 mEq/1 for every 100 mg/dl (5.5 
mmol/1) rise in glucose. As this calculation corrects sodium only and no other 
ECF electrolytes (K
+
, C\~ and HC03
-
), anion gap should not be calculated using 
the corrected sodium value. Hypertonic hyponatraemia is not considered 
pseudohyponatraemia because it is not an artefact of sodium measurement.  
Hypotonic hyponatraemia 
As sodium is the predominant extracellular osmole, most cases of 
hyponatraemia are hypotonic and can be further classified based on the patient's 
volume status as (i) hyponatraemia with contracted ECF volume (hypovolaemia); 
(ii) hyponatraemia with expanded ECF volume (hypervolaemia); and (iii) 
hyponatraemia with normal ECF volume (euvolaemia). For a diagnosis of 
hypotonic hyponatraemia, the effective osmolality must be < 275 mOsm/kg of 
water.  
Hypovolaemic-hypotonic hyponatraemia 
Depletional hyponatraemia results from decreased sodium intake or 
increased losses of sodium, contraction of ECF and appropriate increase in ADH 
secretion with subsequent free water retention. It is often accompanied by the 
physical findings of extracellular volume deficit such as flat neck veins, 
decreased skin turgor, dry mucous membranes, orthostatic hypotension and 
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tachycardia. 
Examination of the urinary Na
+
 concentration is helpful in assessing 
whether losses are renal/extra renal in origin. Urinary Na
+
 concentration of <20 
mEq/1 reflects a normal renal response to volume depletion and points to an extra 
renal source of Na
+
 loss. In patients with hypovolaemic hyponatraemia, urinary 
Na
+
 concentration in excess of 20 mEq/1 points to the kidney as the source of the 
fluid and Na
+
 losses. 
Hypovolaemic hyponatraemia can be aggravated when fluid losses are 
replaced with hypotonic fluids. When isotonic saline is used, it eliminates the 
stimulus for ADH release, thereby allowing the excess water to be excreted. This 
effect may normalise the plasma sodium concentration rapidly and may be 
undesirable in patients with chronic hyponatraemia (> 48 h). Administration of 
desmopressin or hypotonic solutions may be helpful to slow the rate of sodium 
correction in these patients. 
Although there are many causes of hypovolaemic-hypotonic 
hyponatraemia, the two common aetiologies are diuretic induced and cerebral 
salt wasting (CSW).  
Table 2: Causes of depletional hyponatremia 
 
GI losses 
 
Vomiting 
Diarrhoea 
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Fistulas 
Gastrointestinal suction or drainage tubes 
Third spacing 
of fluids 
 
 
Burns 
Peritonitis 
Bowel obstruction 
Pancreatitis 
Renal losses 
 
 
Adrenal insufficiency 
Proximal renal tubular acidosis - sodium losses induced by bicarbonaturia 
Salt-wasting nephropathy (interstitial nephropathy, medullary cystic 
disease, polycystic kidney disease) 
Presence of an osmotically active non-reabsorbable solute in the urine 
(glycosuria, ketonuria, mannitol, urea) causes renal excretion of sodium 
Severe vomiting with the metabolic alkalosis and bicarbonaturia - sodium 
accompanies bicarbonate in the urine to maintain electroneutrality. 
Cerebral salt wasting 
Diuretic use 
Sweat losses Marathon runners 
 
Diuretics are commonly used in the management of hypertension and 
CHF. A subset of diuretics, especially thiazide containing preparations such as 
the amiloride/ hydrochlorthiazide combination pills, causes significant 
hyponatraemia. ' A similar risk is associated with the use of some antibiotics that 
contribute to the high incidence of hyponatraemia in intensive care units. 
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Hyponatraemia is a potentially fatal complication of thiazide therapy, even 
when low doses (12.5-25 mg/day) are used. It is usually evident within 14 days 
ofonset of therapy, but can occur up to 2 years later. It appears to be more 
common in women and elderly patients with low body weight with an underlying 
tendency of increased water intake. While the initial volume depletion induced by 
thiazides can stimulate the release of ADH, susceptible patients appear to have a 
reduced innate ability to excrete water load. These patients may not have clinical 
features of volume depletion described above and can be also classified as 
euvolaemic hypotonic hyponatraemia. Cerebral oedema is extremely rare even 
when plasma sodium concentration is 115 mEq/1. In many of these patients, 
hyponatraemia is reproducible with a thiazide rechallenge. 
The use of high doses of loop diuretics may result in hypovolaemic 
hyponatraemia by inducing overt volume depletion. Loop diuretics because of 
their effect on urine concentrating ability typically do not cause severe 
hyponatraemia. By preventing active sodium reabsorption in the loop of Henle, 
loop diuretics make the medullary interstitium hypotonic and typically lead to 
excretion of urine with a concentration of about 0.45% saline (75 mEq/1). 
Diuretic induced K
+
 depletion can also lead to hyponatraemia, independent 
of the effects of Na
+
 depletion. Hypokalaemia impairs the urinary concentrating 
ability and can lead to nocturia, polyuria and polydipsia. 
In most cases, diuretic induced hyponatraemia will resolve by 
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discontinuing the diuretic. Once the patient becomes euvolaemic, ADH release 
will be appropriately suppressed and rapid excretion of the excess water occurs. 
If patient is symptomatic, hypertonic saline can be slowly infused for gradual 
sodium correction. 
Another important cause of hypotonic-hypovolaemic hyponatraemia is 
CSW. It is a rare syndrome described primarily in patients with intracranial 
disease such as infections, cerebrovascular accidents, tumours and neurosurgery 
that may lead to renal salt wasting and volume contraction in some patients. The 
mechanisms implicated in impaired renal tubular sodium reabsorption include 
decreased sympathetic tone that normally promotes sodium, uric acid and water 
reabsorption in the proximal tubule, increased production of brain natriuretic 
peptide (BNP) that inhibits renin release and decreases sodium reabsorption in 
proximal and distal tubules. The typical onset of hyponatraemia because of CSW 
is within 10 days following the neurological insult and is rarely seen after 30 
days. 
As SIADH is the most common cause of hyponatraemia in patients with 
intracranial disease, it should be carefully differentiated from CSW. Treatment of 
CSW should be attempted with isotonic saline. Volume repletion will suppress 
the release of ADH resulting in the excretion of the excess water and correction 
of the hyponatraemia. Salt tablets and fludrocortisone can be also be used to treat 
CSW. As CSW is usually transient, long-term therapy is not necessary. 
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Table 3:  Comparative profile of the syndrome of inappropriate ADH 
secretion (SIADH) and cerebral salt wasting (CSW) 
 
Clinical features SIADH CSW 
Plasma sodium Low Low 
ECF volume Normal or slightly 
increased 
Decreased 
Total body water volume I r s  Increased 
Blood pressure Normal May be low 
Postural hypotension Absent Present 
Antidiuretic hormone Increased Increased 
Urine osmolality Inappropriately high Appropriately high 
Urineosmolalityaftervolumeexp
ansion 
 
Relatively fixed Decrease to <100mOsm/kg 
Urinarysodium excretion Increased >40 mEq/1 
because of volume 
expansion 
Increased >40 mEq/1 because 
of salt wasting 
Plasma uric acid level Low due to volume 
expansion 
Low due to urinary losses 
Fractional excretion of urate Normal after correction of 
plasma sodium 
Elevated after correction of 
plasma sodium 
Brain natriuretic peptide Normal Normal to high 
Effect of isotonic saline May worsen 
hyponatraemia 
Improves hyponatraemia 
Treatment Free water restriction, 
hypertonic saline infusion, 
ADH antagonists, loop 
diuretics, high solute 
intake, Demeclocycline 
Salt loading volume 
replacement, fludrocortisone 
acetate 
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Hypervolaemic-hypotonic hyponatraemia 
Hypervolaemic-hypotonic hyponatraemia results from water retention in 
excess of sodium retention in the face of elevated total body sodium content. The 
most common causes are cardiac disease, cirrhosis, renal failure and nephrotic 
syndrome. With the exception of renal failure, these states are characterised by 
avid Na
+
retention (urinary Na
+
concentration <10 mEq/1) that may be obscured 
by the concomitant use of diuretics. 
The decreased ECV in CHF despite increased ECF volume leads to 
activation of the RAA and sympathetic nervous systems along with ADH release 
to promote sodium and water retention. The retained solute and volume 
extravasate from the intravascular space to ECF causing dilutional 
hyponatraemia. Persistent hyponatraemia is associated with an adverse 
short-term and long-term prognosis in patients with acute myocardial infarction 
and heart failure. Restricting water intake combined with angiotensin converting 
enzyme (ACE) inhibitors and loop diuretic is the mainstay of therapy in 
hyponatraemic patients with cardiac dysfunction. Vasopressin receptor 
antagonists such as conivaptan and tolvaptan produce a selective water diuresis 
without affecting sodium excretion and may have a role in the management of 
hyponatraemia associated with heart failure. 
In cirrhosis, ECV is decreased because of splanchnic vasodilatation 
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induced possibly by nitric oxide.This leads to activation of RAA system and 
ADH release, and the latter is roughly proportional to the severity of the cirrhosis. 
Hyponatraemia (<130 mEq/1) is a powerful predictor of prognosis and death, in 
patients with cirrhosis waiting for the liver transplantation. As symptomatic 
hyponatraemia is unusual in cirrhosis, the mainstay of therapy is restricting water 
and salt intake combined with diuretics. Vasopressin receptor antagonists may 
also have a role in the management ofhyponatraemia associated with cirrhosis. 
Nephrotic syndrome typically results in sodium retention induced by the 
renal disease and decreased ECV caused by the low plasma oncotic pressure. The 
incidence of hyponatraemia in the nephrotic syndrome is lower compared with 
both CHF and cirrhosis. 
Sodium and water balance are usually maintained in patients with chronic 
renal failure, until the GFR falls below 10-15 ml/min. Patients with advanced 
renal failure have impaired free water clearance, and the minimum urine 
osmolality is 200-250 mOsm/kg despite the appropriate suppression of ADH. 
Hypervolaemic hyponatraemia occurs when the water intake exceeds the ability 
to excrete equivalent volumes. When hyponatraemia develops in patients with 
renal failure, the plasma osmolality may be normal or high because of the 
retention of urea (ineffective osmole), but their corrected or effective plasma 
osmolality will remain normal and is calculated as follows. 
Corrected plasma osmolality = Plasma osmolality - (BUN + 2.8) 
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Hyponatraemia of chronic renal failure generally responds to the 
combination of dietary sodium and water restriction combined with diuretic 
therapy  
Euvolaemic hypotonic hyponatraemia 
The broad differential diagnosis of Euvolaemic hypotonic hyponatraemia  
includes the syndrome of inappropriate ADH (SIADH),adrenal insufficiency, 
hypothyroidism, medications, exercise-induced . ADH directly or indirectly 
mediates these processes. Beer potomania , primary polydipsia and reset 
osmostat are exceptions to the latter , urinary sodium excretion is typically 
normal in all of the above conditions  ,Only excess ADH release conditions are 
associated with an elevated urine osmolality. 
Decreased GFR and renal plasma flow has been shown to be associated 
with Hypothyroidism.Levels of ADH are elevated with severe hypothyroidism, 
and thyroxine replacement corrects the elevated ADH levels.The impaired water 
excretion in this disorder is being mediated by the excess ADH combined with 
diminished distal fluid delivery 
Glucocorticoids play a pivotal role in the normal water excretion, elevated 
ADH levels are seen in glucocorticoid defeciency.Physiological doses of 
glucocorticoids corrects these elevated ADH levels.Renal hemodynamics gets 
altered in prolonged glucocorticoid deficiency (14-17 days) ,because water 
excretion is impaired by an ADH independent process. 
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Continued ADH secretion and excessive hypotonic fluid intake contributes 
to the exercise-associated hyponatraemia (EAH) seen after endurance exercise 
(e.g. triathlon events and marathons) .  Hypovolaemia because of sweat losses, 
intense exercise pain and emotion constitutes the Non-osmotic stimuli for the 
ADH secretion in endurance athletes . Dizziness, nausea and vomiting to 
seizures, coma and death are the various clinical signs and symptoms due to acute 
hyponatremia seen in exercise associated hyponatremia 
 
Fluid restriction and observation until the onset of a spontaneous diuresis 
should be the management protocol for hyponatraemic patients with mild to 
moderate symptoms . Where as hypertonic saline should be given for those with 
severe neurological symptoms  till the resolution of neurological symptoms. 
Prevention of these conditions can be done by training the endurance athletes to 
drink according to thirst during the race. 
 Primary polydipsia also comes under euvolemic hyponatremia.Water 
consumption  in excess of 10 to 151 a day has been seen in many patients with 
chronic psychiatric illnesses notably schizophrenia .Suppression of ADH 
secretion occurs as a result of this excess water consumption and patient begins to 
excrete dilute urine (osmolality nearly 50mosm/kg) .Maintainence of euvolemia 
also happens as a result of sodium excretion via renal route (urine sodium >20 
mEq/1).  A defect in regulation of thirst centrally possibly plays a pivotal role in 
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the pathogenesis of polydipsia.
43
Acutely psychotic patients are at an increased 
risk for developing hyponatraemia  and   treatement with some antipsychotic 
medications also add on the risk by increasing thirst through anticholinergic side 
effects.  Augmented vasopressin release can be seen in schizophrenic patients 
with hyponatraemia during psychotic exacerbations. Long-term management 
options include limiting the fluid intake, restricting the use of drugs causing dry 
mouth etc. 
The hyponatraemia in beer potomania arises in patients who are 
consuming large amounts of beer along with intake of very low solute .  In 
malnourished patients who are consuming low-protein, high-water diets,a similar 
form of hyponatremia is being described;where the  endogenous protein 
breakdown and urea excretion are suppressed by the high carbohydrate load . 
  Plasma osmolality and plasma sodium are maintained at a lower set point 
in patients with reset osmostat.They can dilute or concentrate the urine in 
response to water loading and dehydration since the functioning of osmoreceptor 
is normal eventhough its set around a new baseline . Patients typically 
presentation occurs within a stable range of  mild to moderate hyponatraemia 
(between 125 and 135 mEq/1). The diagnosis can be confirmed clinically by 
giving excess water and observing the response to this water load, where patients 
with reset osmostat typically excrete >80% of ingested water within few hours. 
Downward resetting of the osmostat is a normal consequence of 
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pregnancy, which results in a decreased plasma osmolality of approximately 10 
mmol/kg and an increase in plasma volume. The shift in osmotic threshold 
appears in the first trimester and persists throughout pregnancy, returning to 
normal by 2 weeks after delivery.
 
Reset osmostat has been also described in 
patients with quadriplegia, psychosis, tuberculosis, chronic malnutrition, 
cachexia, hypothalamic tumours and hypothalamic injury from trauma or 
surgery. As attempting to raise the serum sodium concentration is likely to be 
ineffective, treatment should be primarily directed at the underlying disease. 
Hyponatraemia is also found in up to 50% of hospitalised and 20% of 
ambulatory patients with human immunodeficiency virus (HIV) infection. The 
aetiology is multifactorial and includes SIADH secondary to drugs, 
encephalopathy or secondary infections such as cytomegalo virus, hepatitis C or 
toxoplasmosis, depletion because of chronic diarrhoea, renal tubular toxicity 
associated with therapy and adrenal insufficiency.  
Hyponatraemia of unknown aetiology should prompt a work up for 
neuroendocrine amine precursor uptake and decarboxylating (APUD) tumours as 
well as oat cell, breast and ovarian tumours that are often difficult to detect. 
One of the aetiologies of euvolaemic hypotonic hyponatraemia that is 
commonly diagnosed in hospitalised patients is the SIADH.  
 
Syndrome of inappropriate ADH secretion (SIADH) 
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The SIADH is associated with increased morbidity and mortality of 
hospitalised patients and is a measure of the severity of the underlying illness. 
Under normal circumstances, hypovolaemia and hyperosmolality 'appropriately' 
stimulate ADH secretion. ADH release is considered 'inappropriate' without 
these physiological cues. High levels of vasopressin are secreted intermittently at 
an abnormally low threshold or continuously despite low osmolality. The 
presence of hyponatraemia with a urine osmolality higher than maximal dilution 
confirms the diagnosis. Nausea and pain are potent stimulators of ADH release 
and commonly lead to SIADH in hospitalised postoperative patients. 
Table 4: Drug-induced hyponatraemia causes 
Anti-psychotics Anti-depressants Anti-convulsants 
Analgesics and 
Recreational 
Drugs 
Phenothiazines 
Haloperidol 
SSRI's TCA's Carbamazepine 
Oxcarbazepine 
Morphine (high 
doses), Tramadol, 
MDMA (Ecstasy), 
NSAID's, 
Colchicine, 
Venlafaxine, 
Cymbalta 
(duloxetine) 
Cardiac drugs Anti-diabetics 
Anti-neoplastic 
agents 
Antibiotics 
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Thiazides, 
clonidine, ACE 
inhibitors, 
Aldosterone 
antagonists, 
Amiloride, Loop 
diuretics, 
Methyldopa, 
Amlodipine, 
Amiodarone, 
lorcainide, 
Propafenone, 
Theophylline, 
Terlipressin, 
Unfractionated 
heparin 
(aldosterone 
antagonist) 
Chlorpropamide, 
Tolbutamide, 
Glipizine 
Cyclophosphamide, 
Vincristine, 
Vinblastine 
Cisplatin, 
Hydroxyurea, 
Melphalan 
Azithromycin 
Trimethoprim- 
sulfamethoxazole, 
ciprofloxacin, 
cefoperazone/ 
sulbactam, 
rifabutin 
Lipid lowering 
agents 
Immunosuppressive 
drugs 
Gastrointestinal 
drugs 
Clofibrate Tacrolimus, 
Methotrexate, 
interferon a and y, 
levamisole, 
Monoclonal 
Antibodies 
Somatostatin 
analogs, 
Omeprazole 
Others 
Bromicriptine 
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Table 5: Non-drug induced causes of the syndrome of inappropriate ADH 
Non-osmotic 
stimuli 
CNS lesions Malignancies 
Increased 
intrathoracic 
pressure 
Nausea Tumours 
(neuroblastoma) 
Lymphoma, 
leukaemia, and 
Hodgkin disease 
Mediastinal 
tumours 
(thymoma, 
sarcoma) 
Pain CVA Carcinoma of the 
uterus 
Positive pressure 
ventilation 
Stress Meningitis Ureteral, prostate, 
bladder carcinoma 
Infections 
(pneumonia, TB, 
aspergilosis, long 
abscess) 
HIV Encephalitis Carcinoma of 
duodenum and 
pancreas 
Bronchogenic 
carcinoma, 
mesothelioma 
Acute psychosis Abscess Ectopic production 
of vasopressin by 
tumours (small cell 
lung carcinoma, 
carcinoids) 
Bronchogenic 
carcinoma, 
mesothelioma 
Acute psychosis Abscess Ectopic production 
of vasopressin by 
Bronchiectasis 
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tumours (small cell 
lung carcinoma, 
carcinoids) 
Surgery Guillain-Barre 
syndrome 
Cancers of the head 
and neck and 
nasopharynx 
Empyema 
Pregnancy 
(physiological) 
Hydrocephalus Renal cell 
carcinoma 
Chronic 
obstructive 
pulmonary disease 
Hypokalaemia Pituitary stalk 
lesion 
Osteosarcoma Pneumothorax 
CHF exacerbation Delirium tremens 
Demyelinating 
disease Acute 
porphyria 
Osteosarcoma Pneumothorax 
 
        In many patients, the initiating event of SIADH is ingestion of water that 
is not excreted because of the elevated vasopressin. Although water is retained in 
hyponatraemia, approximately 60% of the excess fluid goes into the cells. This 
leads to the expansion of extracellular and intracellular volume with an 
associated natriuresis of isotonic urine in an effort to bring the ECF volume back 
to normal. 
Sometimes it is difficult to differentiate SIADH from mild to moderate 
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depletional hyponatraemia caused by renal losses (e.g. diuretic use). The 
response of urinary and plasma sodium concentration to an infusion of 1-2 1 of 
0.9% saline may help in the differential diagnosis. In the patient with SIADH 
who is at equilibrium, the administered saline will be excreted and therefore there 
will be an increase in urinary sodium, while plasma sodium concentration will 
either not change or decrease slightly. If the patient has depletional 
hyponatraemia from renal losses, sodium from the administered saline will be 
retained and the excess water is excreted. There will be a decrease in urinary 
sodium, while the plasma sodium concentration will rise. 
Laboratory and clinical features of SIADH include the following: 
(1)Euvolaemic hyponatraemia; 
(2)Decreased measured plasma osmolality (<275 mOsm/kg); 
(3)Urine osmolality > 100 mOsm/kg; 
(4)Urine sodium usually > 40 mEq/1; 
(5)Normal acid-base and potassium balance; 
(6)BUN < 10 mg/dl (3.57 mmol/1); 
(7)Hypouricemia <4 mg/dl (238umol/l); 
(8)Normal thyroid and adrenal function and 
(9)Absence of advanced cardiac, renal, or liver disease. 
There is an over-reliance in clinical practice on plasma: urine osmolality 
ratios that can be misleading and absolute values of plasma and urine osmolality 
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are far better indicators of the diagnosis. In clinical practice, ADH levels are not 
required to be measured in patients with suspected SIADH. However, in some 
clinical centres where ADH assays are readily available, the measurements may 
be helpful. 
It is a common misconception to expect urine osmolality to be higher than 
that of serum osmolality in patients with SIADH. The latter is more often seen in 
patients with depletional hyponatraemia. In euvolaemic patients with SIADH, 
urine osmolality above 100 mOsm/kg is inappropriately high and is an indirect 
measure of persistent ADH secretion. Patients with SIADH may have a low urine 
sodium concentration if they are also volume depleted or if their sodium intake is 
extremely low. In such patients, the diagnosis of SIADH is confirmed by 0.9% 
saline loading as describe above (i.e. the urine sodium rises, but the urine 
osmolality remains high). 
The low BUN and plasma uric acid concentrations in patients with SIADH 
are partly dilutional, but also result from increased urea and uric acid clearances 
in response to the ECF volume expansion.  
Clinical features of hyponatraemia 
Although most hyponatremic patients may appear asymptomatic, severe 
symptomatic hyponatremia is a medical emergency that calls for immediate 
treatment. Signs and symptoms depend on several factors and vary by patient. 
The rate of decline in serum sodium concentration, the patient's age, and the 
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volume of extra cellular fluid (ECF) all affect the clinical presentation.
 
CNS symptoms 
Symptoms are related largely to dysfunction of the central nervous system 
and are more evident when the decrease in the serum sodium concentration is 
large orfast. However, patients also present with non-neurologic symptoms, such 
as fatigue, thirst, weakness, cramping, nausea, vomiting, bloating, swelling, and 
tightness of the hands and feet. Most patients with a serum sodium concentration 
greater than 125 mEq/L or with chronic hyponatremia do not have neurologic 
symptoms, owing to volume adaptation by the brain. 
Gastrointestinal symptoms, such as nausea and vomiting, are more 
common in patients with serum sodium levels between 125 and 130 
mEq/L.Acute hyponatremia (<48 hours in duration) in a previously 
asymptomatic young adult can cause severe central nervous system symptoms 
even at serum sodium levels between 125 and 130 mEq/L. Once the level falls 
below 125 mEq/L, neurologic symptoms predominate. Headache, muscle 
cramps, reversible ataxia, psychosis, lethargy, restlessness, disorientation, 
apathy, anorexia, and agitation are symptoms seen in patients with serum sodium 
levels below 125 mEq/L. 
Clinical signs include abnormal sensorium hypothermia, depressed 
reflexes, pseudobulbar palsy, and Cheyne-Stokes respiration. 
Complications of severe hyponatremia 
37 
 
Complications of severe and rapidly developing hyponatremia 
includeseizures, coma, brainstem herniation, respiratory arrest, permanent brain 
damage, and death. These complications result primarily from hyponatremia 
induced cerebral edema, which is most often seen in patients following surgery or 
in those with primary polydipsia. Menstruating women are also at elevated risk of 
severe neurologic complications associated with hyponatremia. 
Clinically important hyponatremia is a particular challenge in patients with 
acute neurologic diseases such as cerebral salt-wasting syndrome, syndrome of 
inappropriate antidiuretic hormone secretion (SIADH), anoxic or traumatic brain 
injury, or subarachnoid hemorrhage, since the presentations can overlap 
significantly. 
 
Figure 2: Clinical symptoms in severe nyponatremia 
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Distinction between acute and chronic hyponatraemia is clinically 
important because chronic hyponatraemia is surprisingly well-tolerated, even at 
very low levels of serum sodium, and overly aggressive treatment may result in 
serious neurological sequelae. Aggressive initial correction is warranted in 
patients with acute symptomatic hyponatraemia, which can potentially cause 
irreversible neurological damage and death. 
Hyponatraemia is considered acute when it develops within 48 h of prior 
normal plasma sodium levels. Acute hyponatraemia occurs most often with 
intake of large volumes of hypotonic fluids (postoperative patients, marathon 
runners) and also in users of 'ecstasy' (3,4-memylenedioxymethamphetamine, 
MDMA). As a result of osmotic effect, water moves intracellularly and results in 
cerebral oedema. Eventually, the extracellular water is moved into the 
cerebrospinal fluid, and cerebral oedema gradually resolves by extruding sodium 
and potassium salts and certain organic solutes called osmolytes. 
Hyponatraemia is considered chronic if it develops slowly and persists for 
greater than 48 h.
53
 Patients with chronic gradual onset hyponatraemia are 
typically asymptomatic because of the brain adaptation to changes in osmolality. 
This adaptation occurs at the expense of loss of intracellular osmolytes, which 
normally protect the brain from a sudden increase in osmolality of the ECF. In 
these patients, rapid increase in plasma osmolality results in water moving out of 
neurons, leading to shrinkage of cerebral tissue.This is the possible mechanism of 
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central myelinolysis, which was first described in the pons, but can occur 
diffusely throughout the brain. 
Neurological deterioration typically develops over several days with 
fluctuating consciousness, convulsions, hypoventilation and hypotension. 
Eventually, patients may develop pseudobulbar palsy with difficulty in 
swallowing, inability to speak and quadriparesis. Recovery from this syndrome is 
variable, and many neurological complications are permanent. The magnetic 
resonance imaging (MRI) scans demonstrate the demyelinated lesions 3-4 weeks 
after the correction of hyponatraemia. 
Hyponatraemic encephalopathy is more likely to develop in patients who 
suffer a hypoxic event and have underlying severe liver disease, and in 
premenopausal women.As there is no effective therapy after the development of 
central demyelination, prevention is of primary importance.  
MANAGEMENT OF HYPONATREMIA 
To be optimal, therapy for hyponatremia must be individualized. In all 
patients, the risk of hyponatremia-associated complications must be balanced 
against the risk of serum sodium correction. Several important factors should be 
considered when deciding on treatment, including the following: 
• The rapidity of onset of hyponatremia 
• The degree, duration, and symptomatology of hyponatremia 
• The presence or absence of risk factors for neurologic complications.  
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Acute symptomatic hyponatremia 
Acute symptomatic hyponatremia develops in less than 48 hours. Clinical 
manifestations are largely related to central nervous system dysfunction resulting 
from brain cell swelling. Patients are at particular risk for this condition during 
the perioperative period. Once the serum sodium level falls below 125 mEq/L, 
neurologic symptoms predominate. In acute severe and rapidly developing 
hyponatremia, the risk of complications of cerebral edema exceeds the risk of 
osmotic demyelination associated with too-rapid correction of serum sodium, so 
treatment should begin promptly. 
Prompt, controlled correction of the serum sodium level is indicated for 
patients with acute symptomatic hyponatremia. The goal is to raise the serum 
sodium level by 1.5 to 2 mEq/L/hour until symptoms subside 1 or until the 
concentration has risen to a safer level—usually greater than 118 to 120 mEq/L, 
with the primary focus being to minimize the risk of seizures. Even in 
symptomatic patients, the sodium level should not be raised by more than 12 
mEq/L in the first 24 hours and by more than 18 mEq/L in the first 48 hours, in 
order to avoid osmotic demyelination (central pontinemyelinolysis). 
Infusion of hypertonic saline (3%) at a rate of 1 to 2 mL/kg/hour and 
addition of a loop diuretic, to enhance water excretion, are commonly used to 
achieve this goal.Hypertonic saline may be infused at a rate of 4 to 6mL/kg/hour 
if severe neurologic symptoms, particularly seizures, are present. Once a patient 
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is asymptomatic and sodium levels are greater than 118 mEq/L, correction should 
be slowed to no more than 8 mEq/L in 24 hours to achieve a target level of 125 
mEq/L.
 
In all cases, close and frequent monitoring of serum sodium and 
electrolytes is mandatory until sodium levels increase and symptoms subside.  
Chronic symptomatic hyponatremia 
In hyponatremia of unknown duration, or of more than 48 hours' duration, 
sodium correction should be managed very cautiously because of significant 
osmotic adaptation of the brain to prolonged hyponatremia. In patients presenting 
with severe symptoms, treatment should be similar to that for acute symptomatic 
hyponatremia: hypertonic saline plus a loop diuretic. Careful monitoring is 
critical because of an increased risk of irreversible osmotic demyelination. 
Correction should be limited to no more than 10 to 12 mEq/L on the first day of 
treatment and less than 6 mEq/L/day thereafter. In patients presenting with mild 
to moderate symptoms, slower correction is required, generally 0.5mEq/L/hour. 
Once the desired correction is achieved, therapy may continue in the form of fluid 
restriction.  
Chronic asymptomatic hyponatremia 
The goal in treating asymptomatic hyponatremia is to prevent a further 
decline in serum sodium and to maintain levels as close to normal as possible. 
Treatment involves a more conservative approach than for symptomatic 
hyponatremia. Initially, underlying causes of hyponatremia should be 
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investigated and treated; this should include evaluation for drug-induced 
hyponatremia. Fluid restriction, isotonic saline, and loop diuretics maybe used to 
treat the hyponatremia. 
Euvolemic hyponatremia is the most common form of asymptomatic 
hyponatremia. If the underlying cause is SIADH and its etiology is unknown or 
cannot be effectively treated, therapy should be instituted for the hyponatremia 
itself. '
5
In cases where the etiology of SIADH is known (e.g. tumor), the 
underlying cause should be treated or removed in addition to correcting the serum 
sodium level. 
Management of the SIADH should begin with water restriction and 
treatment of the underlying aetiology, such as stopping inciting medications, 
treatment of nausea, pain, infections and chemotherapy for cancer. In all patients 
with hyponatraemia, free water intake from all sources should be restricted to less 
than 1-1.5 1/day. The negative water balance caused by water restriction will 
gradually increase the serum sodium concentration. In patients with mild 
symptoms, the rate of urinary solute excretion, the main determinant of the urine 
output, can be increased by a high salt, high protein diet or supplementation with 
urea (30-60 g/dl) or salt tablets (200 mEq/day). However, salt therapy is 
generally contraindicated in patients with hypertension and oedema, as it leads to 
exacerbation of both conditions. 
Symptomatic or severe hyponatraemia generally requires hospitalisation 
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for observation, careful monitoring of fluid balance and body weight and 
frequent measurements of plasma sodium concentrations. Giving hypotonic 
fluids in the setting of elevated ADH levels can produce severe and 
life-threatening hyponatraemia. Electrolyte concentrations and osmolalities of 
commonly used intravenous fluids are listed below: 
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Table 6:  Electrolyte concentration and osmolality of commonly used 
intravenous fluids 
11 
infusate* 
Na
+ 
(mEq/1) 
C1 
(mEq/I) 
H20 
(ml) 
Change in 
ICF 
(ml) 
Change in ECF (ml) 
Osmolality 
(mOsm/kg) Total 
Intra-vas
cular 
0.9% 
saline 11 
154 154 0 0
+
 1000
+
 250 ml
+
 308 
3% saline 
11** 
513 513 0 
Decreased 
due to 
osmotic 
shift 
1000+ 
water 
drawn 
from ICF 
Increased 1026 
5% saline 
11** 
855 855 0 
Decreased 
due to 
osmotic 
shift 
1000+ 
water 
drawn 
from ICF 
Increased 1710 
Ringer's 
lactate 11 
130 109 0 100 900 225 273 
0.45% 
saline 11 
77 77 500 335 665 166 154 
D5W 0 0 1000 667 333 83 253 
ICF=Intracellular fluid; ECF=Extracellular fluid; TBW=Total body water. 
* Assumes: ICF=2/3
rd
 TBW; ECF=l/3
rd
 TBW; Intravascular (plasma) 
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volume=l/4
,h
 ECF. 
+ Only in patients with normal plasma osmolality. Hypertonic for a patient with 
hyponatraemia. ** Changes in ECF and ICF volume are dependent on patient's 
degree of hyponatraemia. 
One can directly calculate the degree to which saline infusate would 
initially raise the plasma sodium concentration. The increase in plasma Na 
concentration (P(Na )) can be calculated with the following equation: 
Estimated increase in P[Na
+
] = (Infusate [Na
+
] - P[Na
+
]) + (TBW) 
As such computed estimates are not capable to precisely predict the 
magnitude of change, the sodium concentration should be monitored as 
frequently as every 1-2 h. It isalso noteworthy that normal (0.9%) saline is 
usually sufficient for the management of most cases of hyponatraemia, and the 
risk of cerebral symptoms with hypertonic saline is significant unless close 
monitoring is performed. 
A recent alternative to saline administration in the management of 
hyponatraemia is the use of ADH receptor antagonists. The most specific 
treatment for SIADH is to block the V2 receptors in the kidney that mediate the 
diuretic effect of ADH. Vasopressin antagonists are currently indicated for the 
treatment of euvolaemic and hypervolaemic hyponatraemia, and these agents are 
usually preferred if SIADH or ADH is the cause. For hospitalised patients, 
conivaptan is given as an intravenous loading dose of 20 mg delivered over 30 
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min, then as 20 mg continuously over 24 h. Subsequent infusions may be 
administered every 1-3 days at 20-40 mg/day by continuous infusion. Rapid 
correction of hyponatraemia has been reported in patients receiving conivaptan. 
Therefore, frequent checks of plasma sodium are needed. Each vial (20 mg/4 ml) 
of conivaptan typically costs approximately $500 and when used over 3 days at 
the recommended doses, the total cost of such infusion could reach $3000. 
More recently, an orally active vasopressin receptor antagonist tolvaptan 
became available. The efficacy of oral tolvaptan in ambulatory patients with 
SIADH, heart failure and cirrhosis has been recently demonstrated. V2-receptor 
antagonists are not suitable for certain causes of hyponatraemia, such as CSW 
syndrome, psychogenic polydipsia and potomania. 
While SIADH is frequently a transient phenomenon, a chronic phase can 
occur in patients with ectopic ADH producing tumours and in patients where 
antipsychotic drugs cannot be discontinued. If water restriction and salt tablet 
therapy are ineffective in these patients, the following drug therapy to antagonise 
the effect of ADH could be attempted: (i) administration of loop diuretic along 
with salt tablets; (ii) demeclocycline; (iii) lithium carbonate; and (iv) orally active 
vasopressin antagonists such as tolvaptan. 
Administration of loop diuretic (20 mg furosemide orally twice a day) 
along with salt tablets will not only antagonise the effect of ADH but also 
prevents the oedema formation by the latter. 
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Demeclocycline (300-600 mg orally twice a day) inhibits the effect of 
ADH in the collecting tubule.Its onset of action may require 1 week, and urinary 
concentrating ability may be permanently impaired, resulting in nephrogenic 
diabetes insipidus and even hypernatraemia. Demeclocycline is nephrotoxic in 
patients with cirrhosis and is contraindicated in children because of interference 
with bone development and teeth discoloration. 
Lithium carbonate (300 mg orally twice a day) also inhibits the effect of 
ADH. It is less effective than demeclocycline and when used chronically, it may 
induce interstitial nephritis and renal failure. Therefore, lithium should be 
considered for use only in patients in whom demeclocycline is contraindicated, 
such as children and patients with liver disease.
  
Table 7: Treatment options for hyponatremia 
Treatment Mechanism Limitations 
Fluidrestriction 
(most common) 
Induces negative water 
balance 
Increases plasma osmolality 
and serum sodium 
No direct inhibition of excess 
hormone 
No inhibition of hormone on 
kidneys 
Nonadherence 
Demeclocycline Impairs AVP action at renal 
tubules 
Induces nephrogenic diabetes 
insipidus 
Nephrotoxicity (cirrhosis 
patients) Hypersensitivity Drug 
interactions Unsafe in 
pregnancy 
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Reduces urine concentration, 
even with increased AVP 
levels 
Urea Decreases sodium excretion Hypersensitivity 
Unsafe in pregnancy 
Azotemia 
Liver failure 
Can reduce effects of lithium 
Phlebitis, thrombosis 
Lithium Impairs AVP at renal tubules Inconsistent results 
Lithium toxicity 
Anti-anabolic effects mainly in 
cirrhosis and congestive heart 
failure 
Unsafe in pregnancy 
Diuretics 
(loop/thiazide) 
Increase water excretion by 
inhibiting sodium and chloride 
reabsorption in loop of Henle and 
distal tubule 
Hypersensitivity 
Hepatic coma 
Anuria 
Severe electrolyte depletion 
 
COMPLICATION OF TREATMENT 
Central Pontine Myelinolysis (CPM) has traditionally been associated with 
rapid correction of hyponatremia, but the etiology has not been clearly 
established. 
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 PATHOGENESIS 
The pathogenesis of CPM is unknown, but the theories such as the osmotic 
hypothesis of CPM have implicated hyponatremia and its rapid correction in 
some cases.It is postulated that cells conditioned to a hypoosmotic hyponatremia 
environment may have a decreased adaptive capacity to osmotic stress. 
The predilection of the myelinolysis to the pons is thought to be a result of 
the grid arrangement of the oligodendrocytes in the base of the pons, which limits 
their mechanical flexibility and therefore their capacity to swell. During 
hyponatremia these cells can only adapt by losing more ions instead of swelling, 
making them prone to damage when sodium is replaced. Proximity to the 
extensively vascularised gray matter makes the pons particularly susceptible to 
damage caused by vasogenicodema and myelinotoxic substances from vessels.
  
CLINICAL PRESENTATION 
The clinical presentation is highly variable, can present with a rapidly 
evolving paraparesis or quadriparesisand pseudobulbar palsy. They may present 
with locked in syndrome, in which intellectual activity is preserved but cannot be 
expressed. Less often it can manifests with ataxia, other movement disorders or 
behavioural symptoms.  
DIAGNOSIS 
Diagnosis of CPM is based on clinical suspicion and is confirmed by 
imaging studies. MRI is the primary method for diagnosis and is superior to CT. 
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during the acute phase, symmetrical and hypointense lesions on a TI weighted 
MRI can be identified.In comparison, during the subacute phase there are 
symmetrical and 
hypointense lesions in T2 weighted images. 
MANAGEMENT 
The most important step in the management of CPM is recognising the 
patient at risk and preventing rapid correction of hyponatremia-especially 
chronic severe hyponatremia.  Once a diagnosis is made, the management of 
CPM is mainly supportive.  
Treatment modalities 
• Thyrotropin releasing hormone 
• Methylprednisolone 
• Plasmapheresis 
• Immunoglobulins. 
The exact mechanism of action of TRH, corticosteroids, and 
plasmapheresis is unknown. A conservative approach with treatment of the 
precipitating or underlying conditions and appropriate supportive care in severe 
cases may be justified in the absence of studies confirming the efficacy of the 
above mentioned treatments. 
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 REVIEW OF LITERATURE 
In a hospital based descriptive study of symptomatic hyponatremia in elderly 
patients conducted by Rao et al. including 100 patients with symptomatic 
hyponatremia, they concluded hyponatremia is  commoner among females and 
females will tolerate hyponatremia better than their male counterparts. Lethargy 
(feeling of tiredness), irrelevant talk and drowsiness with delayed latent period 
and slow response were concluded as most common problems noticed by the 
patient. Around 61% of patients were assigned to be euvolemic, 23% were found 
to be overloaded and 16% found to be dehydrated. Isovolemic hyponatremia was 
concluded to be the most common type. The common causes of hyponatremia 
were SIADH(30%) followed by drugs(25%). 
Mahavir, Agarwal et al compared the clinical and aetiological profile of 
low serum sodium presenting to the emergency department with that developing 
during the in- hospital stay .common symptoms were concluded as confusion 
(41%), headache (40%) and malaise (38.6%). Most common cause was found to 
be poor intake(82.9%),and increased losses was found to be the next common 
cause. 31.4% developed low serum sodium during their in-hospital stay. Most 
common precipitating events for the hyponatremia in hospitalised patients were 
found to be due to improper ryle’s tube feeding,volume overload and drugs. 
In a study done on the etiology and the frequency of hyponatremia in adult 
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hospitalized patients in medical wards of a general hospital by Thomas Vurgese 
et al. overall incidence of hyponatremia was 3.6%. Out of these 56% were males 
and 44% were females. The commonest age group affected was 45-64 years.  
The mean serum sodium levels were 122 mmol/litre. 59.1% patients 
presented during earlier summer months as compared to 40.9% who presented 
during winter months. Commonest cause of hyponatremia was concluded as 
SIADH due to pneumonia.
 
 
      Miyashita J et al., in a study on impact of low serum sodium and SIADH 
on mortality in aged patients with pneumonia due to aspiration, concluded that 
low serum sodium levels due to SIADH had a strong correlation with increased 
death rate in elderly patients. out of 221 cases 29% were suffering from low 
serum sodium levels. Of these 95% had hypotonic hyponatremia, which were 
further assessed as having hypovolemic (63%), hypervolemic (5%) and 
euvolemic (32%) hyponatremia. Of the euvolemic patients 70% had SIADH. 
There were significant increase in mortality with both severe and moderate 
decrease in serum sodium levels.30 day mortality was significantly higher in 
adult patients with SIADH 
Rubio Rivas H et al. conducted a study on geriatric patients with low serum 
sodium levels and assessed its prevalence and prognosis. The sample consisted of 
52.7% females and 47.2% males. Mean age was 83.7 years. Mean plasma sodium 
values were 137.3 mmol/litre. Emergency lab test showed, out of 60 patients with 
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hyponatremia 35 were in Acute geriatric care unit. Most common predisposing 
factors were cardiopulmonary illnesses. Mean hospital length of stay was 12.8 
days. In-hospital mortality was 12.9%).  
          They observed a statistically significant association between mean 
serum sodium levels and duration of hospital stay. No significant association was 
found between serum sodium levels and death rate. 
         Chua M et al. studied on prognostic implications of hyponatremia in 
elderly patients and concluded that low serum sodium levels during initial 
presentation were strongly associated with increased mean length of in hospital 
stay and advanced dependence. This cohort study measured the prognostic 
impact of hyponatremia in all patients admitted to 2 acute geriatric wards. Basic 
demographic data and serum sodium results were included in multiple linear and 
logistic regression models for the end points, length of stay and return to previous 
residence respectively. There were 103 cases (mean age 82, 59% females),of 
whom 18% were hyponatremic on admission, but another 23% became 
hyponatremic whilst in hospital. Median length of stay was 13 days. 65% cases 
returned to the previous residence on discharge, 8% died. Factors independently 
associated with longer length of stay were increasing age, lower admission serum 
sodium and larger drop in serum sodium during admission. Only a larger drop in 
serum sodium was significantly associated with failure to return to previous 
residence.  
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                      MATERIALS AND METHODS 
SOURCE OF DATA 
The study was conducted in Madurai medical college during the period 
from april to September 2016. Patients aged ≥ 60 years admitted with serum 
sodium < 135 meq/1 were included in the study. 
INCLUSION CRITERIA 
Subjects aged ≥ 60 years with serum sodium < 135 meq/1 (Government of India 
defines 'senior citizen' or 'elderly' as a person who is of age60 years or above) 
Patients with euvolemic hyponatremia(SIADH,hypothyroidism etc 
 
EXCLUSION CRITERIA 
Patients aged < 60 years  
Serum sodium ≥135 meq/1  
Patients with hypovolemic and hypervolemic hyponatremia(CCF,CKD,CLD) 
MATERIALS AND METHODS 
Clinical assessment 
Detailed history: (based on inclusion and exclusion criteria ).This included 
history of symptoms of hyponatremia, predisposing factors and pre-existing 
illness if present. The definition of symptomatic hyponatremia was based on a 
clinical assessment of symptomatology including the presence of altered 
sensorium, postural dizziness, lethargy and seizures. Sensorium changes 
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included acute confusional states, memory disturbances, stupor, delirium and 
coma. Drugs that can cause hyponatremia were recorded. History of illness 
causing hyponatremia such as CCF, CKD, CLD,(exclusion criteria ) 
hypothyroidism and other conditions which are associated with SIADH such as 
small cell carcinoma, CNS disease were taken. History of fluid loss as in 
vomiting, diarrhoea, diuretic use, exceesive sweating were taken in all patients 
Physical examination: Detailed clinical examination was done in every 
patient. Hydration status of the patient was determined by clinical examination. 
The signs of hypovolemia included tachycardia, decreased skin turgor, dry 
mucous membranes and decreased peripheral perfusion. Hypervolemic state was 
defined by the presence of anasarca,ascites, bilateral pitting pedal oedema and 
raised JVP. Accordingly patients were divided into hypervolemic, hypovolemic 
and euvolemic. 
SIADH and CSW were differentiated on the basis of volume status of the 
patient,urine osmalility after volume expansion,treatement and response to 
treatement. 
At the time of diagnosis of hyponatremia, detailed CNS examination was 
done to document mental status of the patient and other focal neurological deficit. 
CNS examination was repeated after the correction of hyponatremia and the 
presence of symptoms such as dizziness, lethargy, altered sensorium and seizures 
were attributed to hyponatremia unless there was a co-existing medical condition 
or medication effect to account for these symptoms. Patients were screened for 
CPM based on clinical grounds that is development of confusion, agitation and 
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flaccid or spastic paralysis during or after correction of hyponatremia.  
Investigations 
1. CBC: Hb, TLC, DC, Plt count 
2. URE, microscopic examination and specific gravity 
3. Serum sodium: Serum sodium was done daily for symptomatic cases, 
alternate days for asymptomatic patients. 
4. Serum BUN and glucose levels: For calculation of serum osmolality. 
5. Serum osmolality was calculated by the formula 
Serum osmolality = 2(sodium) + RBS/18+BUN/2.8 
Patients were divided into 
• Isotonic - 280-295 mosm/1 
• Hypotonic - <280 mosm/1 
• Hypertonic - >295 mosm/1 
6. Urine osmolality- in patients with hypotonic hyponatremia. 
 (normal range-300-900 mosm/kg) 
7. Urine sodium- in hypotonic hyponatremic patient. 
(normal range-40-220 meq/1) 
8. Brain imaging and CSF analysis in patients presenting with altered sensorium 
to exclude structural abnormalities and meningeal infection. 
9. Serum protein and lipid profile to rule out pseudohyponatremia 
10. Thyroid function test and serum cortisol 
Management and Outcome Assessment 
Patients with hyponatremia were classified based on serum sodium levels 
into following categories 
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Category Serum sodium levels 
Mild 130-135 meq/1 
Moderate 125-129meq/l 
Severe <125 meq/1 
Treatment Strategy 
Decision on the treatment modality was based on the cause and severity of 
hyponatremia and presence of neurological symptoms of hyponatremia. 
1. Fluid restriction - defined as total fluid intake in 24 hrs equal to the volume 
of urine output of previous 24 hrs. It was advised in patients with SIADH. 
2. Normal saline (0.9%) - given to hypovolemic patients.{eg. CSW } 
3. Loop diuretic - given for excretion of free water in cases of SIADH . 
4. 3% saline - in severe hyonatremic patients with neurological symptoms of 
hyponatremia. 
Data Collection 
For all patients clinical and demographic details, final diagnosis, 
investigations and management were recorded onto a standard data collection 
sheet as per the study proforma and later transferred to Microsoft excel 
spreadsheet for analysis.  
Statistical Analysis 
Analysis was done using SPSS for windows (version 20.0). Statistical 
method used was descriptive and analytical statistics. Data are presented as 
frequency distribution and simple percentages.Analysis were done using 
probability tests. 
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RESULTS 
Table 8: Age-wise distribution 
Age Group (years) Number Percentage 
60-70 39 78 
71-80 7 14 
>80 4 8 
Total 50 100 
Graph 1: Age-wise distribution 
 
 
 
The maximum number of patients were in the age group 60-70 years, i.e. 
39 cases (78%), 14% were in 71-80 group and 8% were in >80 group. 
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Table 9: Gender-wise distribution 
Gender Number Percentage 
Male  30 60 
Female 20 40 
Total 50 100 
 
Graph 2: Gender-wise distribution 
 
 
 
In the study out of 50,60% were males and 40% were females. 
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Table 10: Age and gender distribution 
Age group 
(years) 
Male Female 
Number Percentage Number Percentage 
60-70 23 46 16 32 
71-80 4 8 0 0 
>80 3 6 4 8 
Total 30 60 20 40 
 
Graph 3: Age and gender distribution 
 
 
Out of the 30 males 23 falls in the age group of 60-70. Out of 20 females, 16 are 
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in the age group of 60-70. There were no females in the age group of 71-80 in the 
study. 
Table 11: Symptomatology of hyponatremia 
Symptoms Number Percentage 
Asymptomatic 29 58 
Lethargy 21 42 
Postural dizziness 3 6 
Abnormal behaviour 16 32 
Seizures 2 4 
Coma 0 0 
 
Graph 4: Symptomatology of hyponatremia 
 
    The majority of the cases were asymptomatic at time of presentation, 58%. 
Out the symptomatic cases, 42%, 100% had lethargy, 76% had abnormal 
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behaviour, 14% had postural dizziness and 9% (2 cases) had seizures. None of the 
patients were in coma. 
Table 12: Severity of hyponatremia 
Sodium levels 
(mmol/litre) 
Number Percentage 
130-135 (Mild) 11 22 
125-129 (Moderate) 8 16 
<125 (Severe) 31 62 
Total 50 100 
 
Graph 5: Severity of hyponatremia 
 
 
Out of 50 cases majority 62% were having severe hyponatremia, 16% were 
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having moderate hyponatremia and 22% were having mild hyponatremia. 
Table 13: Correlation of symptoms with levels of hyponatremia 
Symptoms Mild Moderate Severe 
Asymptomatic 11 8 10 
Lethargy 0 0 21 
Postural dizziness 0 0 3 
Abdominal 
behaviour 
0 0 16 
Seizures 0 0 2 
Coma 0 0 0 
 
Graph 6: Correlation of symptoms with levels of hyponatremia 
 
Out of 29 asymptomatic patients 11 were having mild hyponatremia, 10 were 
having severe hyponatremia and 8 were having moderate hyponatremia. All the 
symptomatic patients were having severe hyponatremia. 
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Table 14: GCS score and level of hyponatremia 
 
Levels of 
hyponatremia 
GCS score 
≥13 8 to 12 <8 
Mild 11 0 0 
Moderate 7 1 0 
Severe 17 14 0 
Total 35 15 0 
 
Graph 7: GCS score and level of hyponatremia 
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All the mild hyponatremic patients (11) had GCS≥13. Out of 8 moderate 
hyponatremic patients 7 had GCS≥13 and 1 had GCS 8-12. Out of 31 severe 
hyponatremic patients 17 had GCS≥13 and 14 had GCS 8-12. None of the 
patients hadGCS<8 
Table 16: Predisposing factors 
 
Predisposing factor 
 
Number 
 
Percentage 
 
Drugs 
 
4 
 
8 
 
Nonosmotic stimuli 
/others 
 
2 
 
4 
 
Cns lesions 
 
12 
 
24 
 
Malignancy 
 
11 
 
22 
 
Endocrine Causes 
 
14 
 
28 
 
Pulmonary Diseases 
 
7 
 
14 
 
Graph8:Predisposingfactors
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Cns infections and endocrine causes constitute the major predisposing 
Factors ;followed by malignancy and pulmonary diseases 
Table 17: Etiology of euvolemic hyponatremia 
 
 
 
 
 
 
 
 
drugs
cnsinfection
malignancy
endocrine
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Etiology 
 
 
 
Number 
 
Percentage 
Hypothyroidism 
 
             13                                 
26 
Adrenal insufficiency 
 
              2                             
4 
Drugs  
 
              9                            
18 
Exercise induced 
 
              3                              
6 
SIADH 
 
             18                             
36 
Primary polydipsia 
 
              2                               
4 
Others  
 
              3                                         
6 
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Graph 9: Etiology of euvolemic hyponatremia 
       
 
 
Out of 50 cases most common etiology was SIADH .About 36 % had 
SIADH.26% had hypothyroidism.18 % were having drug induced hyponatremia . 
6 % with exercise induced, and other causes like reset osmostat. 
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Table 18: Outcome 
Days for normalising sodium Number 
1 to3 17 
4to7 22 
Not recovered 2 
Not assessed 9 
Total 50 
 
Graph 10: Outcome 
 
 
The days for normalising sodium were noted during the study. For 17 
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cases, 1-3 days were needed, 22 cases needed 4-7 days. 2 cases had not 
recovered. One was a case of hypothyroidism and another case of SIADH with 
poor intake and vomiting. 9 cases were not assessed as 8 patients got discharged 
against medical advises and one patient died the next day of admission following 
IHD. No complications occurred due to treatment of hyponatremia. 
Relation between serum sodium and other parameters 
Association between serum sodium and age 
Age PATIENTS 
Mean 
Na 
SD 
60-65 29 120.766 8.895 
66-70 10 121.85 10.794 
71-75 2 108.65 7.566 
76-80 5 117.82 10.201 
81-85 4 117.825 7.491 
Total 50     
Overall Mean 67.08 119.968 9.321 
Age vs Na 
0.411 
NS 
    
 
P value of 0.411 . no significant association with age and serum sodium level. 
 
 
Mean age 67.08 
 
Mean serum sodium 119.968 (s.d : 9.321 )  
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Relation between serum sodium level and symptoms 
 
 
 
Symptoms Sodium 
level 
SD 
Asymptomatic 123.55 8.971 
Dizziness 112 9.849 
Seizure 118 8.485 
Lethargic 115 7.475 
Abnormal 
Behaviour 
114.75 7.688 
p value 0.002  
Sig 
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There is significant association between serum sodium values and symptoms. 
 
 
Relation between outcome and serum sodium levels 
 
 
 
 
OUTCOME Sodium 
level 
SD 
Complete 
recovery (38) 
121.64 9.506 
Residual 
defects (3) 
117.5 5.766 
Expired (1) 115 1 
Nil (8) 113.64 7.272 
p value (38/50  
vs 12/50) 
0.023 
Sig 
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p value of .023 ; there is significant association between serum sodium values and 
outcome. 
 
 
Relation between age of the patient and outcome. 
 
 
 
OUTCOME 
Age PATIENTS CR NA Death RD 
60-65 29 21 6 1 1 
66-70 10 8 1 0 1 
71-75 2 2 0 0 0 
76-80 5 3 1 0 1 
81-85 4 4 0 0 0 
+Total 50 38 8 1 3 
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P value of .013 ,there is significant association between age of the patient and 
recovery. 
 
 
 
 
 
Relation between sex of the patient and outcome. 
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Sex PATIENTS CR NA Death RD 
Male 30 22 5 1 2 
Female 20 16 3 0 1 
Total 50 38 8 1 3 
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Pvalue –  0.551.There is no significant correlation between sex of the patient and 
outcome. 
 
 
Relation between outcome and serum sodium levels 
 
 
OUTCOME Sodium 
level 
SD 
Complete 
recovery (38) 
121.64 9.506 
Residual 
defects (3) 
117.5 5.766 
Expired (1) 115 1 
Nil (8) 113.64 7.272 
p value (38/50  
vs 12/50) 
0.023 
Sig 
 
 
 
0
5
10
15
20
25
CR NA Death RD
22 
5 
1 
2 
16 
3 
0 
1 
SEX VS OUTCOME 
Male
75 
 
 
 
There is significant association between serum sodium levels and outcome.(p 
value of 0.023 ) 
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DISCUSSION 
This study was undertaken keeping in view of frequent occurrence of 
hyponatremia in the elderly sick patients who are at higher risk of development of 
electrolyte disturbance as these people have age related physiological changes in 
the function of kidneys and other multiple co-morbid conditions. 
 
In the present study 50 elderly patients (≥60 years) were included. Out of 
50, 60% (30) were males and 40% (20) were females. 
In study done by Rao et al. 55 were females and 45 were male. In study by 
Mahavir et al. 64.3% were males and 53.7% were females. In study by Rubio et 
al. 52.7% were females and 47.3% were males. In study by Vurghese et al. males 
were 56.1%, females 43.9% 
In the present study majority, 78%(39) of the cases were in the age group 
60-70 years. 14% were in 71-80 group and only 8% were in > 80 group. 
Out of the 30 males 23(46%) falls in the age group of 60-70. Out of 20 
females 16(32%) are in the age group of 60-70. There were no females in the age 
group of 71-80 in the study. 
The majority of the cases were asymptomatic at time of presentation, 58%. 
Out the symptomatic cases, 42%, 100%> had lethargy, 76% had abnormal 
behaviour, 14% had postural dizziness and 9% (2 cases) had seizures. Both the 
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patients had GTCS, had recovered when serum sodium normalised. None of the 
patients were in coma. 
In study Rao et al., lethargy, drowsiness with slow response and irrelevant 
talk were the common presenting symptoms. 4% had seizures. 
In study by Mahavir et al. confusion was present in 30% and altered sensorium in 
17.1%. 2% had seizures. 14% were asymptomatic. 
        When hyponatremia develops more gradually,cerebral neurons have the 
time to respond by reducing the intracellular osmolality,through reduction in cell 
potassium and by reduced synthesis and efflux of intracellular organic 
osmolytes.The osmotic gradient favoring water movement into the cells is thus 
reduced , and patients may present with minimal or no symptomatology. 
In the present study 62% had severe hyponatremia, 22% had moderate 
hyponatremia and 16% had mild hyponatremia. This could not be compared with 
other studies because the range of hyponatremia of mild, moderate and severe is 
different in this study. 
In the present study out of 29 asymptomatic patients, 11 were having mild 
hyponatremia, 10 were having severe hyponatremia and 8 were having moderate 
hyponatremia. All the symptomatic patients were having severe hyponatremia. 
When the GCS score was compared, all the mild hyponatremic patients 
(11) had GCS ≥13. Out of 8 moderate hyponatremic patients 7 had GCS ≥13, 1 
had GCS 8-12. Out of 31 severe hyponatremic patients 17 had GCS≥ 13, 14 had 
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GCS 8-12. None of the patients had GCS <8. 
         In the study by Rao et al., 61% were euvolemic, 23% were overloaded 
and 16% dehydrated. The commonest type of hyponatremia noted in the study 
was euvolemic hypo-osmolar hyponatremia. 
In the study by Miyashita et al. 95% had hypotonic hyponatremia out of 
which 63% had hypovolemia, 5% had hypervolemia and 32% euvolemia. 
In the present study out of 50 patients, most common predisposing factor 
was endocrine causes followed by cns lesions followed by malignancy and 
pulmonary diseases 
In the present study out of the cases most common etiology was SIADH, 
about 36% had SIADH.26% had hypothyroidism.18% having drug induced 
hyponatremia, 6% with exercise induced and other causes 
In the study by Rao et al. common causes were SIADH (30%) followed by 
drugs (24%). 
In study by Varghese et al. most common etiology was SIADH (34.8%), 
CKD (19.69%), CCF (18.18%), 6% of DM, HTN, cirrhosis and 3% acute 
gastroenteritis. 
In the study by Mahavir et al. decreased intake (82.9%) was the most 
common etiology, increased loss (65.7%) was also present as second most 
common cause. 
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The days for normalising sodium were noted during the present study. For 
17 cases 1-3 days were needed, 22 cases needed 4-7 days. 2 cases had not 
recovered. One was a case of hypothyroidism and another case of SIADH with 
poor intake and vomiting. 9 cases were not assessed as 8 patients got discharged 
against medical advise and one patient died the next day of admission following 
IHD. No complications occurred due to treatment of hyponatremia. 
In study by Rao et al., 20 patients died secondary to hyponatremia 
In study by Mahavir et al., time taken for recovery was 3.7±2.4 days. No 
mortality was observed. 
In study by Rubios et al., in-hospital mortality due to hyponatremia was 
12.9%. 
In study by Chua et al. mean length of hospital stay was 13 days. Mortality 
rate was 8% out of 103 cases.  
There is significant association between serum sodium levels and 
symptoms and with outcome of the patients.Also study found out association 
between age of the patient and outcome.In the study done by Rao et al indicate a 
higher mortality in the elderly patients with severe hyponatremia. 
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 CONCLUSION 
 
Hyponatremia is a common electrolyte abnormality found in hospitalised 
patients. It is more common in elderly patients. 
      Lethargy was the most common symptom. Other common 
symptoms were abnormal behaviour and postural dizziness. All the symptomatic 
cases had severe hyponatremia. There is significant association between serum 
sodium levels and symptoms and with outcome of the patients.Also study found 
out association between age of the patient and outcome. 
           Most common etiology was SIADH. Other major causes were 
hypothyroidism,drugs,exercise. Hyponatremia was found to be related to 
multiple etiological factors in a large number of patients. 
Treatment of hyponatremia with hypertonic saline should be restricted to 
patients who are symptomatic. Treatment with hypertonic saline is safe provided 
gradual correction of hyponatremia is followed. 
Osmotic demyelination is a rare complication related to the treatment of 
hyponatremia and should be suspected in a case of hyponatremia who develop 
fresh neurological deficits while on treatment or after treatment with hypertonic 
saline. 
A systematic approach to the diagnosis of hyponatremia with the 
81 
 
application of simple diagnostic algorithms, using history, clinical examination 
and laboratory findings to establish mechanism of hyponatremia can significantly 
improve the management and outcome of hyponatremia. 
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SUMMARY 
Hyponatremia is the most common electrolyte disorder in hospitalised 
patients particularly in elderly. Hyponatremia is important to recognise because 
of the potential morbidity, mortality and the economic impact on the patient and 
health care. Studying the risk factors, etiology and management of hyponatremia 
in hospitalised patients will help in reducing its incidence and minimising the 
complications associated with hyponatremia. 
The study was conducted in a tertiary care centre . Successive patients of 
hyponatremia were included in the study. These patients were evaluated for the 
underlying cause of hyponatremia which included detailed history and physical 
examination followed by appropriate laboratory investigations based on serum 
osmolality. 
Fifty patients were included in the study. 58% were asymptomatic at time 
of presentation. Out of symptomatic cases 100% had lethargy, 76% had abnormal 
behaviour and 14% had postural dizziness. There was wide range of etiologies, 
most common being SIADH (36%). Hypertonic saline was given to 54%, fluid 
restriction was advised for 44%, 10% were given normal saline. One patient had 
died during the study, cause of death being IHD. No complications were reported 
during treatment of patients with hyponatremia. Treatment with hypertonic saline 
is safe provided gradual correction of hyponatremia is followed. 
There is significant association between serum sodium levels and 
83 
 
symptoms and with outcome of the patients.Also study found out association 
between age of the patient and outcome. 
Osmotic demyelination is a rare complication related to the treatment of 
hyponatremia and should be suspected in a case of hyponatremia who develop 
fresh neurological deficits while on treatment or after treatment with hypertonic 
saline. 
Hyponatremia is a common problem in hospitalised patients. The possible 
cause of hyponatremia should always be determined, as outcome in severe 
hyponatremia is governed by etiology and not by serum sodium level. The 
correction of hyponatremia also helps to improve the prognosis of the underlying 
disease and helps to prevent further complications due to the hyponatremia itself. 
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LIMITATIONS OF THE STUDY 
 
1. Smaller study group 
2. Only short term mortality and morbidity are assessed. Long term morbidity 
in the form of re-admission  and long term mortality are not assessed. 
3. Male to female ratio was not similar to most of other studies. 
4. The etiology of hyponatremia in older people is predominantly 
multifactorial, with patients presenting with doubtful signs of hydration. 
5. In the present study 62% had severe hyponatremia, 22% had moderate 
hyponatremia and 16% had mild hyponatremia. This could not be 
compared with other studies because the range of hyponatremia of mild, 
moderate and severe is different in this study. 
6. The study population involved patients seeking  medical care in a tertiary 
care centre and hence may not represent the general population. 
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LIST OF ABBREVIATIONS 
 
ACE        Angiotensin converting enzyme 
ADH        Anti diuretic hormone 
ANP        Atrial natriuretic peptide 
APUD        Amine precursor uptake and decarboxylating 
AVP        Arginine vasopressin  
BNP        Brain natriuretic peptide 
BUN        Blood urea nitrogen 
CBC        Complete blood count 
CCF        Congestive cardiac failure 
CHF   Congestive heart failure 
CKD   Chronic kidney disease 
CLD   Chronic liver disease 
CNS   Central nervous system 
CPM   Central pontine myelinolysis 
CSF   Cerebro spinal fluid 
CSW   Cerebral salt wasting 
CVA   Cerebrovascular accident 
D5W   5% dextrose 
DC   Differential count 
DM   Diabetes mellitus 
EAH   Exercise associated hyponatremia 
ECF   Extra cellular fluid 
ECV   Effective circulating volume 
GCS   Glasgow Coma Scale 
GFR  Glomerular filtration rate 
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GTCS        Generalised tonic clonic seizures 
Hb        Haemoglobin 
HCO3   Bicarbonate ion 
HIV        Human immune deficiency virus 
HTN   Hypertension 
ICF   Intra cellular fluid 
IHD   Ischaemic heart disease 
ISE   Ion selective electrode 
JVP   Jugular venous pulse 
K
+   Potassium ion 
MAOI   Mono amine oxidase inhibitors 
MDMA   3,4-methylene dioxy meth amphetamine 
MRI   Magnetic resonance imaging 
Na
+   Sodium ion 
NSAID   Non-steroidal anti inflammatory drug 
Pit   Platelet 
RAA   Renin angiotensin aldosterone 
SIADH   Syndrome of inappropriate anti diuretic hormone 
SSRI   Selective serotonin re-uptake inhibitors 
TB   Tuberculosis 
TBW   Total body water 
TCA   Tri cyclic anti depressants 
TLC   Total leucocyte count 
TRH   Thyrotropin releasing hormone 
TURP   Trans urethral resection of prostrate 
URE   Urine routine examination 
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                        PROFORMA 
CASE NO. 
NAME: 
AGE: 
SEX: 
ADDRESS: 
CHIEF COMPLAINTS 
HISTORY OF PRESENT ILLNESS 
PAST HISTORY 
FAMILY HISTORY 
PERSONAL HISTORY 
PROVISIONAL DIAGNOSIS 
CLINICAL EXAMINATION 
P.R. 
B.P. 
RESPIRATORY RATE 
PALLOR-YES/NO 
ICTERUS-YES/NO 
OEDEMA-YES/NO 
SKIN TURGOR AND ORAL CAVITY: NORMAL/MILD DEHYDRATION/ 
      MARKED DEHYDRATION 
SIGNS OF PERIPHERAL CIRCULATORY FAILURE: YES/NO 
GOITRE: YES/NO 
SIGNS OF HYPOTHYROIDISM: YES/NO 
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CNS EXAMINATION 
CONSCIOUS/ABNORMAL BEHAVIOUR/DROWSY/STUPOR/COMA 
CRANIAL NERVE DEFICITS-YES/NO 
MOTOR SYSTEM 
DTJ- NORMAL/BRISK/DEPRESSED 
PLANTARS: FLEXOR/EXTENSOR/MUTE 
GAIT ATAXIA: YES/NO 
CEREBELLAR SIGNS: PRESENT/ABSENT 
GCS:/15 
RESPIRATORY: 
CVS: 
ABDOMEN: 
PROFILE OF INVESTIGATIONS 
Hb(g/dl) 
TLC 
DLC 
Plt count 
S.Na
+
 
S.K
+
 
s.cr 
BUN 
S.Creatinine 
RBS 
Total Protein 
S. albumin 
S. cholesterol 
S.LDL 
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FINAL DIAGNOSIS 
PREDISPOSING FACTOR 
DIURETIC USE: YES /NO 
VOMITING: YES/NO 
SWEATING: YES/NO 
CNS INFECTION/SURGERY: YES/NO 
POOR INTAKE: YES /NO 
DIARRHOEA: YES/NO 
HYPOTONIC FLUID USE: YES/NO 
PULMONARY DISEASE: YES /NO 
SYMPTOMS PERTAINING TO HYPONATREMIA 
ASYMPTOMATIC: YES/NO 
POSTURAL DIZZINESS: YES/NO 
SEIZURES: YES/NO 
LETHARGY: YES/NO 
ABNORMAL BEHAVIOUR: YES/ NO 
COMA: YES/NO 
PRE-EXISTING ILLNESS 
DIABETES: YES/NO 
CHRONIC LIVER DISEASE: YES/NO 
CONGESTIVE HEART FAILURE: YES/NO 
HYPERTENSION: YES/NO 
CKD: YES/NO 
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HYPOTHYROIDISM: YES/NO 
COURSE IN HOSPITAL: 
SPECIFIC INVESTIGATIONS 
Plasma osmolality 
Urine RE 
Urine sp. Gravity 
Urine osmolality 
Urine Na
+
 
Urine K
+
 
TREATMENT GIVEN IN HOSPITAL 
MANAGEMENT DETAILS 
0.9% SALINE 
3.0% SALINE 
DIURETICS 
WATER RESTRICTION 
POTASSIUM REPLACEMENT 
DURATION FOR NORMALISATION OF S.Na
+
 
DURATION FOR CLINICAL RECOVERY 
COMPLICATIONS DURING THERAPY 
RECURRENCE OF HYPONATREMIA 
LIKELY CAUSE OF RECURRENCE 
FINAL OUTCOME: COMPLETE RECOVERY/ RESIDUAL DEFICITS/DEATH 
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KEY TO MASTER CHART 
ABD  Abdomen 
ABN  Abnormal 
ABN BE  Abnormal behaviour 
ALB  Albumin 
ASY   Asymptomatic 
BBC   Bilateral basal creps 
BP   Blood pressure 
BUN   Blood urea nitrogen 
C                   -    Crepitations 
CCF   Congestive cardiac failure 
CKD   Chronic kidney disease 
CL   Chloride 
CLD   Chronic liver disease 
CND   Cranial nerve deficits 
CNSI/S   CNS infection/surgery 
COM   Complication 
Cr   Creatinine 
CR   Complete recovery 
CS   Cerebellar signs 
Csl                  -    serum cortisol 
CVS   Cardiovascular system 
CYN   Cyanosis 
D   Drowsy 
DEP   Depressed 
DHY   Dehydration 
DIA   Diarrhoea 
DIZZ   Dizziness 
DM   Diabetes mellitus 
DNN   Duration of normalising sodium 
DTJ   Deep tendon reflexes 
E   Extensor 
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F   Female 
Fl   Flexor 
FLU   Fluid 
GA   Gait ataxia 
GALL   Gallop 
GCS   Glasgow coma score 
HEP   Hepatomegaly 
HFU   Hypotonic fluid use 
HTN   Hypertension 
HYPO   Hypothyroidism 
ICT   Icterus 
K   Potassium 
KR   Potassium replacement 
LDL   Low density lipoprotein 
LETH   Lethargy 
LOC   Level of consciousness 
M   Male 
Mu   Mute 
N   No 
Na   Sodium 
NA   Not assessed 
NAD   No abnormality detected 
NOR   Normal 
NR   Not recovered 
NS   Normal saline 
OED   Oedema 
PAL   Pallor 
PC   Pus cell 
Pl.Osm   Plasma osmolality 
PLANT   Plantar 
POI   Poor intake 
PR   Pulse rate 
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PUL D/S   Pulmonary disease 
RBS   Random blood sugar 
RD   Residual deficit 
REC   Recurrence 
RES   Respiratory 
RHON   Rhonchi 
RR   Respiratory rate 
S.Choi   Serum cholesterol 
SEI   Seizures 
SUG   Sugar 
SWE   Sweating 
T.Pro   Total protein 
TSH                -    Thyroid stimulating hormone 
U.Na   Urine sodium 
U.Osm   Urine osmolality 
URE   Urine routine examination 
VOM   Vomiting 
WR   Water restriction 
Y   Yes 
3%   3% saline
  
 
